Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Pharmacokinetics and Exposure-Response of Luspatercept in Patients with Beta-Thalassemia: Preliminary Results from Phase 2 Studies

Nianhang Chen, Abderrahmane Laadem, MD, Dawn M. Wilson, Xiaosha Zhang, Matthew L. Sherman, MD, Steve Ritland, Kenneth M. Attie, MD

Blood (2016) 128 (22): 2463.

https://doi.org/10.1182/blood.V128.22.2463.2463

Published: 2016

Journal Articles

Pharmacokinetics and Exposure-Response of Luspatercept in Patients with Anemia Due to Low- or Intermediate-1-Risk Myelodysplastic Syndromes (MDS): Preliminary Results from Phase 2 Studies

Nianhang Chen, Abderrahmane Laadem, MD, Dawn M. Wilson, Xiaosha Zhang, Matthew L. Sherman, MD, Steve Ritland, Kenneth M. Attie, MD

Blood (2016) 128 (22): 1990.

https://doi.org/10.1182/blood.V128.22.1990.1990

Published: 2016

Journal Articles

Interim Results of a Phase I Study of Lenalidomide (CC-5013) Plus Intraventricular/Intravenous Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma

James L. Rubenstein, MD, PhD, Paul Formaker, Xiaomin Wang, PhD, Nianhang Chen, PhD, Michael Seider, MD, Pamela Munster, MD, Bertil Damato, MD, PhD

Blood (2014) 124 (21): 4470.

https://doi.org/10.1182/blood.V124.21.4470.4470

Published: 2014

Journal Articles

Population Pharmacokinetics and Exposure-Safety Of Lenalidomide In Patients With Multiple Myeloma, Myelodysplastic Syndromes and Mantle Cell Lymphoma

Nianhang Chen, PhD, Ene Ette, PhD, Simon Zhou, PhD, Daniel Weiss, MD, Maria Palmisano, MD

Blood (2013) 122 (21): 3234.

https://doi.org/10.1182/blood.V122.21.3234.3234

Published: 2013

Journal Articles

Phase I Study Of P-Glycoprotein (P-gp) Mediated Drug Interactions Between Lenalidomide (LEN) and Quinidine Or Temsirolimus

Nianhang Chen, PhD, Daniel Weiss, MD, Josephine Reyes, DVM, Liangang Liu, PhD, Claudia Kasserra, PhD, Xiaomin Wang, PhD, Simon Zhou, PhD, Gondi Kumar, PhD, Lilia Weiss, MD, Maria Palmisano, MD

Blood (2013) 122 (21): 5395.

https://doi.org/10.1182/blood.V122.21.5395.5395

Published: 2013

Journal Articles

Exposures and Erythropoietic Responses to Sotatercept (ACE-011) in Healthy Volunteers and Cancer Patients: Implications for Mechanism of Action

Nianhang Chen, Ph D, Adberrahmane Laadem, MD, Matthew L. Sherman, MD, Simon Zhou, PhD, Victoria Sung, PhD, Maria Palmisano, MD, Rajesh Chopra, MD, PhD

Blood (2012) 120 (21): 3454.

https://doi.org/10.1182/blood.V120.21.3454.3454

Published: 2012

Journal Articles

Multicenter Phase I Dose-Escalation Study of Lenalidomide in Patients with Relapsed Adult T-Cell Leukemia-Lymphoma (ATL) or Peripheral T-Cell Lymphoma (PTCL).

Naokuni Uike, MD, PhD, Michinora Ogura, Yoshitaka Imaizumi, MD, PhD, Norio Asou, MD, PhD, Atae Utsunomiya, MD, PhD, Toshiki Uchida, Tomohiro Aoki, Kunihiro Tsukasaki, MD, PhD, Jun Taguchi, MD, Ilseung Choi, MD, Dai Maruyama, MD, PhD, Kisato Nosaka, MD, PhD, Nianhang Chen, Ph D, Tetsuhiro Shiota, Kensei Tobinai, MD, PhD

Blood (2012) 120 (21): 2737.

https://doi.org/10.1182/blood.V120.21.2737.2737

Published: 2012

Journal Articles

Pharmacokinetics (PK) of Lenalidomide When Administered Alone or in Combination with Dexamethasone in Chinese Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): The MM-021 Trial

Nianhang Chen, PhD, Dao-bin Zhou, MD, Li Yu, Jay Mei, MD, PhD, Liangang Liu, Xiaomin Wang, Honeylet Wortman-Vayn, Jian Hou, MD, PhD

Blood (2012) 120 (21): 5046.

https://doi.org/10.1182/blood.V120.21.5046.5046

Published: 2012

Journal Articles

Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome

Rami S. Komrokji, Jeffrey E. Lancet, Arlene S. Swern, Nianhang Chen, Jennifer Paleveda, Richard Lush, Hussain I. Saba, Alan F. List

Blood (2012) 120 (17): 3419–3424.

https://doi.org/10.1182/blood-2012-03-415661

Published: 2012

Journal Articles

Pharmacokinetics, Efficacy and Safety of Lenalidomide (Len) in Myeloma Patients with Renal Impairment: Results From the Prospective Study “REVIR”

Frank Bridoux, Bertrand Arnulf, MD, PhD, Stephane Moreau, Eric Moumas, Nianhang Chen, May Alakl, Estelle Desport, Valerie Neel, Arnaud Jaccard, Jean Paul Fermand, MD

Blood (2011) 118 (21): 2934.

https://doi.org/10.1182/blood.V118.21.2934.2934

Published: 2011

Journal Articles

Two-Stage Pharmacokinetic & Efficacy Study of Lenalidomide Alone or Combined with Recombinant Erythropoietin (EPO) in Lower Risk MDS EPO-Failures [PK-002].

Alan F. List, MD, Jeffrey E. Lancet, MD, Magda Melchert, MD, Hussein Saba, MD, Richard Lush, PhD, Jian Yu, PhD, Nianhang Chen, PhD, Michele Schmidt, RN, Robert Knight, MD

Blood (2007) 110 (11): 4626.

https://doi.org/10.1182/blood.V110.11.4626.4626

Published: 2007

NARROW

Pharmacokinetics and Exposure-Response of Luspatercept in Patients with Beta-Thalassemia: Preliminary Results from Phase 2 Studies

Pharmacokinetics and Exposure-Response of Luspatercept in Patients with Anemia Due to Low- or Intermediate-1-Risk Myelodysplastic Syndromes (MDS): Preliminary Results from Phase 2 Studies

Interim Results of a Phase I Study of Lenalidomide (CC-5013) Plus Intraventricular/Intravenous Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma

Population Pharmacokinetics and Exposure-Safety Of Lenalidomide In Patients With Multiple Myeloma, Myelodysplastic Syndromes and Mantle Cell Lymphoma

Phase I Study Of P-Glycoprotein (P-gp) Mediated Drug Interactions Between Lenalidomide (LEN) and Quinidine Or Temsirolimus

Exposures and Erythropoietic Responses to Sotatercept (ACE-011) in Healthy Volunteers and Cancer Patients: Implications for Mechanism of Action

Multicenter Phase I Dose-Escalation Study of Lenalidomide in Patients with Relapsed Adult T-Cell Leukemia-Lymphoma (ATL) or Peripheral T-Cell Lymphoma (PTCL).

Pharmacokinetics (PK) of Lenalidomide When Administered Alone or in Combination with Dexamethasone in Chinese Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): The MM-021 Trial

Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome

Pharmacokinetics, Efficacy and Safety of Lenalidomide (Len) in Myeloma Patients with Renal Impairment: Results From the Prospective Study “REVIR”

Two-Stage Pharmacokinetic & Efficacy Study of Lenalidomide Alone or Combined with Recombinant Erythropoietin (EPO) in Lower Risk MDS EPO-Failures [PK-002].

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only